American Innovation and R&D Competitiveness Act of 2025
Summary
HR1990, the American Innovation and R&D Competitiveness Act, would restore immediate expensing for R&D costs, reversing the 2022 tax code change that required 5/15-year amortization. This is an early-stage bill referred to Ways and Means with 81 cosponsors, but if enacted, it would provide a direct 21% tax-rate cash flow benefit annually to every R&D-intensive US company. The largest absolute beneficiaries are mega-cap tech and pharma firms with $10B+ annual R&D budgets.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1990 would restore immediate R&D expensing, directly increasing after-tax cash flow for every R&D-intensive US company by 21% of their R&D spend annually
- 2.Largest absolute beneficiaries are mega-cap tech and pharma with $10B+ R&D budgets: $AMZN, $GOOGL, $MSFT, $AAPL, $NVDA, $MRK, $LLY, $PFE
- 3.Bill is early stage (referred to Ways and Means), has 81 Republican cosponsors, no Senate companion — passage is not imminent and requires significant legislative momentum
Market Implications
A bill restoring immediate R&D expensing is structurally bullish for US R&D-intensive companies. The tax mechanism directly improves free cash flow by allowing companies to deduct R&D costs in Year 1 rather than spreading over 5 years. For $MSFT, $AAPL, and $NVDA — each with $10B-$30B in annual R&D — the cash flow benefit is $2-6B per year. For $AMZN, at $60B R&D, the annual benefit exceeds $12B. The bill is not priced into current valuations because of its early stage; passage would represent a meaningful tax cut for the growth sectors of the US economy. Failure to pass (or prolonged delay) maintains the current amortization regime, which is a headwind for high-R&D companies relative to the pre-2022 tax treatment.
Full Analysis
-
What happened: On March 10, 2025, Rep. Estes (R-KS) introduced HR1990 to restore immediate expensing for qualified R&D costs under IRC §174. The Tax Cuts and Jobs Act of 2017 required R&D costs to be amortized over 5 years (US) or 15 years (foreign) starting in 2022 — this bill would repeal that provision. The bill has 81 cosponsors (all Republicans), was referred to Ways and Means, and has no further action after introduction. It is classified as an early-stage bill with 3 total actions, all on the same day.
-
The money trail: This is a tax expenditure — it reduces federal revenue by the amount of R&D spending companies immediately deduct vs. amortizing over 5 years. HR1990 does not authorize or appropriate any spending; it changes tax treatment. The estimated revenue impact is a reduction in corporate tax receipts equal to 21% of total US business R&D annually (approximately $60-80B/year based on aggregate US R&D spend of $300-400B). This is a DIRECT cash flow benefit to R&D-intensive companies with no procurement or contract mechanism — companies simply pay less tax.
-
Structural winners: The largest US R&D spenders are the direct beneficiaries. By absolute dollar, the winners are: $AMZN (~$60B R&D), $GOOGL (~$45B), $MSFT (~$30B), $AAPL (~$30B), $NVDA (~$12B), $MRK (~$14B), $PFE (~$12B), $LLY (~$11B). By sector, semiconductors, cloud software, biotech/pharma, and industrial innovators ($CAT, $DE, $GE) benefit most. Smaller-cap R&D-intensive companies benefit proportionally more relative to market cap but in smaller absolute dollars.
-
Competitive landscape: HR1990 does not pick winners by sector — it benefits any US corporation with R&D expenses. However, the structural impact favors companies with high R&D-to-revenue ratios (tech, pharma) over asset-heavy, low-R&D sectors (utilities, real estate, consumer staples). For $AMZN and $GOOGL with massive cloud R&D, the bill directly supports margin expansion without requiring top-line growth. For $UNH, the Optum health-tech R&D spend qualifies — a secondary beneficiary.
-
Timeline: HR1990 is at the earliest legislative stage (referred to committee, no hearings yet). Passage probability is low-to-moderate in the 119th Congress given the partisan nature of tax bills and limited cosponsorship (81 total, all Republican). The earliest action would be a Ways and Means markup, then House floor vote, then Senate Finance Committee consideration. Given no companion Senate bill with matching text, the legislative path is long — likely 12-18 months minimum if it gains momentum. Related bills (HR3967, S1639, S2056) show bipartisan interest in R&D expensing but no unified vehicle.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Tax change: immediate expensing for R&D costs vs. current amortization requirement
Who must act
Companies filing US corporate tax returns with R&D expenditures qualifying under IRC §174
What happens
Reduction in taxable income by amount of annual R&D spend, improving after-tax cash flow by 21% of R&D expenses in year incurred
Stock impact
MSFT spent approximately $30B on R&D in FY2025; immediate expensing would reduce tax liability by ~$6.3B annually vs. current 5-year amortization schedule, directly improving free cash flow
What the bill does
Tax change: immediate expensing for R&D costs vs. current amortization requirement
Who must act
Companies filing US corporate tax returns with R&D expenditures qualifying under IRC §174
What happens
Reduction in taxable income by amount of annual R&D spend, improving after-tax cash flow by 21% of R&D expenses in year incurred
Stock impact
AAPL spent approximately $30B on R&D in FY2025; immediate expensing would reduce tax liability by ~$6.3B annually, significantly boosting net income and cash available for buybacks or investment
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $895M Department of Veterans Affairs Contract
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
FISHER SAND & GRAVEL CO: $847M Department of Homeland Security Contract
To amend the Export Control Reform Act of 2018 to provide for expedited consideration of proposals for additions to, removals from, or other modifications with respect to entities on the Entity List, and for other purposes.
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Streamlining Access to Government Services Through America.gov
The executive order directs the General Services Administration to create America.gov, a unified digital portal for federal services, integrating Login.gov for authentication and requiring agencies to expose their digital services via APIs. It also mandates the use of AI (referred to as 'super intelligence') with transparency safeguards, while preserving existing service channels and excluding tax and defense/intelligence services.
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Restriction on Entry of Certain Nonimmigrant Workers
This proclamation extends for an additional 12 months the existing restriction on entry of H-1B nonimmigrant workers, which requires a $100,000 payment per petition (with limited exceptions) and is supported by a DHS weighted selection process that prioritizes higher-skilled, higher-paid workers. The action continues to target IT staffing and outsourcing firms that have abused the program, and it maintains the requirement for ongoing rulemakings by DHS and DOL to further reform wage protections and program integrity.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →